Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Dragon Pharma Sells EPO Unit

publication date: Nov 16, 2007
Dragon Pharmaceuticals has sold its EPO business to an unidentified purchaser for $2.1 million. Pointing out that the product contributed just 3% of its revenues, Dragon said it preferred to concentrate on its higher growth antibiotics business. A market study, according to Dragon, shows the EPO market may be trending lower over the next three years. Dragon also announced that antibiotic sales have increased from $31.2 million for all of 2005 to about $60 million for just the first nine months of 2007, which was a 60% increase over the comparable 2006 figure. More details...

Stock Symbol: (OTCBB: DRUG)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here